1. Home
  2. PK vs ADPT Comparison

PK vs ADPT Comparison

Compare PK & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Hotels & Resorts Inc.

PK

Park Hotels & Resorts Inc.

HOLD

Current Price

$10.87

Market Cap

2.1B

Sector

Real Estate

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$16.54

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PK
ADPT
Founded
1946
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.5B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
PK
ADPT
Price
$10.87
$16.54
Analyst Decision
Hold
Strong Buy
Analyst Count
11
10
Target Price
$11.45
$16.60
AVG Volume (30 Days)
3.4M
2.7M
Earning Date
10-30-2025
02-10-2026
Dividend Yield
9.22%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,541,000,000.00
$252,754,000.00
Revenue This Year
N/A
$50.81
Revenue Next Year
$2.07
$1.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
42.57
52 Week Low
$8.27
$5.91
52 Week High
$15.12
$20.76

Technical Indicators

Market Signals
Indicator
PK
ADPT
Relative Strength Index (RSI) 53.26 50.47
Support Level $10.64 $16.33
Resistance Level $10.94 $17.04
Average True Range (ATR) 0.26 0.72
MACD 0.01 0.04
Stochastic Oscillator 67.95 66.19

Price Performance

Historical Comparison
PK
ADPT

About PK Park Hotels & Resorts Inc.

Park Hotels & Resorts owns upper-upscale and luxury hotels, with 22,395 rooms across 36 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks: